Shares of Genus plc (LON:GNS – Get Free Report) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,818.83 ($23.55) and traded as high as GBX 1,970 ($25.50). Genus shares last traded at GBX 1,952 ($25.27), with a volume of 7,896,197 shares.
Analyst Ratings Changes
Separately, Shore Capital restated a “buy” rating on shares of Genus in a report on Wednesday, December 11th.
Get Our Latest Stock Report on Genus
Genus Stock Down 2.7 %
Genus (LON:GNS – Get Free Report) last released its earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.52) EPS for the quarter. Genus had a net margin of 1.18% and a return on equity of 1.41%. As a group, equities research analysts forecast that Genus plc will post 70.9644323 EPS for the current year.
Insider Buying and Selling
In other Genus news, insider Jorgen Kokke sold 19,967 shares of Genus stock in a transaction on Friday, February 28th. The shares were sold at an average price of GBX 1,731 ($22.41), for a total transaction of £345,628.77 ($447,473.81). 0.75% of the stock is owned by company insiders.
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Recommended Stories
- Five stocks we like better than Genus
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Top 3 Beverage Stocks Pouring Out Profits
- 3 Best Fintech Stocks for a Portfolio Boost
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.